Nabriva Therapeutics (FRA:NTY) Other Current Receivables : €0.00 Mil (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Nabriva Therapeutics Other Current Receivables?

Nabriva Therapeutics's Other Current Receivables for the quarter that ended in Jun. 2023 was €0.00 Mil.

Nabriva Therapeutics's quarterly Other Current Receivables declined from Dec. 2022 (€1.00 Mil) to Mar. 2023 (€0.00 Mil) but then stayed the same from Mar. 2023 (€0.00 Mil) to Jun. 2023 (€0.00 Mil).

Nabriva Therapeutics's annual Other Current Receivables increased from Dec. 2020 (€2.09 Mil) to Dec. 2021 (€2.42 Mil) but then declined from Dec. 2021 (€2.42 Mil) to Dec. 2022 (€1.00 Mil).

Nabriva Therapeutics Other Current Receivables Historical Data

The historical data trend for Nabriva Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Other Current Receivables Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Current Receivables

Get a 7-Day Free Trial

2.39

1.09

2.09

2.42

1.00

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Other Current Receivables	Get a 7-Day Free Trial															-	-	1.00	-	-

Nabriva Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Nabriva Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (FRA:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (FRA:NTY) » Definitions » Other Current Receivables

Comparable Companies

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (FRA:NTY) Headlines

No Headlines